Liver function

肝功能
  • 文章类型: Journal Article
    碱性磷酸酶(ALP)在一定程度上反映了多发性骨髓瘤(MM)患者病情的变化。然而,MM中ALP的关系仍不确定。我们的研究旨在确定新诊断的MM患者的初始ALP水平与总体生存率之间的关系。
    收集2012-2016年北京朝阳医院202例新诊断MM患者的临床资料。基线特征,疾病进展分期,血清标记物,并记录患者生存数据.ALP的截止值是根据患者生存数据计算的,并将患者分组。患者3年和5年生存率的差异,肝功能,比较各组间骨病等指标。采用COX回归分析确定影响初诊MM患者的独立危险因素。
    根据ALP截止点将患者分为三组:第1组(ALP<70U/L),第2组(ALP70至<120U/L),和第3组(ALP≥120U/L)。在乳酸脱氢酶中观察到显着差异,血清钙,白细胞计数,血红蛋白,和肝功能指标(包括丙氨酸转氨酶,天冬氨酸转氨酶,白蛋白,和γ-谷氨酰转移酶)在不同ALP组之间(P<0.05)。不同骨病分级患者ALP水平差异有统计学意义(P<0.05)。第1、2和3组的中位生存时间分别为25、52和31个月。分别。第2组的3年生存率明显高于其他两组(P=0.006)。3组5年生存率差异无统计学意义(P=0.51)。年龄,国际分期系统分期,天冬氨酸转氨酶,β2-微球蛋白,ALP分级,严重骨病是影响初诊患者生存的独立因素(P<0.05)。
    ALP水平与MM患者的预后相关,ALP范围为70至<120U/L反映了更好的生存预期。
    UNASSIGNED: Alkaline phosphatase (ALP) reflects changes in the condition of multiple myeloma (MM) patients to some extent. However, the relationship of ALP in MM remains uncertain. Our study aimed to determine the association between initial ALP levels and overall survival in newly diagnosed MM patients.
    UNASSIGNED: Clinical data from 202 newly diagnosed MM patients at Beijing Chaoyang Hospital between 2012 and 2016 were collected. Baseline characteristics, disease progression staging, serum markers, and patient survival data were recorded. The cut-off value for ALP was calculated based on patient survival data, and patients were divided into groups. Differences in patients\' 3- and 5-year survival rates, liver function, bone disease and other indicators among different groups were compared. Independent risk factors influencing newly diagnosed MM patients were identified using COX regression analysis.
    UNASSIGNED: Patients were categorized into three groups based on ALP cut-off points: Group 1 (ALP <70 U/L), Group 2 (ALP 70 to <120 U/L), and Group 3 (ALP ≥120 U/L). Significant differences were observed in lactate dehydrogenase, serum calcium, white blood cell count, hemoglobin, and liver function indicators (including alanine aminotransferase, aspartate aminotransferase, albumin, and γ-glutamyl transferase) among different ALP groups (P<0.05). ALP levels varied significantly among patients with different bone disease grades (P<0.05). Median survival times for Groups 1, 2, and 3 were 25, 52, and 31 months, respectively. Group 2 exhibited significantly higher 3-year survival compared to the other two groups (P=0.006), while no significant difference was observed in 5-year survival among the three groups (P=0.51). Age, International Staging System staging, aspartate aminotransferase, β2-microglobulin, ALP grading, and severe bone disease were identified as independent factors influencing survival in newly diagnosed patients (P<0.05).
    UNASSIGNED: ALP levels are correlated with the prognosis of MM patients, and an ALP range of 70 to <120 U/L reflects a better survival expectation.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:在评估肝功能时,必须区分结构性吲哚菁绿(ICG)排泄缺陷。最近有报道称,由于SLCO1B3基因的同源改变而导致的OATP1B3表达缺失可诱导ICG排泄缺陷;然而,其与临床检查的相关性以及异质性SLCO1B3基因改变的临床意义尚不清楚.
    方法:在评估15分钟ICG保留率(ICGR15)和tech-99m-半乳糖基血清白蛋白(99mTc-GSA)肝闪烁显像后,在49例接受肝切除术的患者中评估了OATP1B3的表达。此外,在无OATP1B3表达的患者中分析了SLCO1B3的改变.随后,对59例接受肝切除术治疗的结直肠癌肝转移(CRLM)患者进行分析。
    结果:在49例患者中,6(12%)的OATP1B3表达缺失。他们的ICGR15值明显更高(74.7%vs.23.5%;p<0.0001),更好的修饰白蛋白-胆红素(ALBI)等级(≤2A级,100%vs.42%;p=0.010),更正常的99mTc-GSA肝闪烁显像(100%vs.28%;p=0.0003),和更好的病理性肝纤维化(F0-1,100%vs.49%;p=0.027)与具有OATP1B3表达的那些相比。三个可用的无OATP1B3表达的病例冷冻块显示SLCO1B3纯合改变。在59例正常肝脏背景的CRLM患者中,5例(8.5%)在SLCO1B3中有杂合插入,但与其他患者相比,他们的ICGR15值或其他临床表现没有差异.
    结论:结构性ICG排泄缺陷可能由OATP1B3表达的完全缺失定义。改良的ALBI等级和99mTc-GSA肝闪烁显像可用于检测结构性ICG排泄缺陷。
    OBJECTIVE: Constitutional indocyanine green (ICG) excretory defects must be distinguished when assessing liver function. The absence of OATP1B3 expression due to homogenous alterations in the SLCO1B3 gene has been recently reported to induce ICG excretory defects; however, its association with the clinical examinations and the clinical implications of heterogeneous SLCO1B3 gene alteration remain unclear.
    METHODS: OATP1B3 expression was evaluated in 49 patients who underwent hepatectomy after evaluation of the ICG retention rate at 15 min (ICGR15) and technetium-99 m-galactosyl serum albumin (99mTc-GSA) hepatic scintigraphy. Additionally, alterations in SLCO1B3 were analyzed in patients without OATP1B3 expression. Subsequently, 59 patients who underwent hepatectomy for colorectal liver metastasis (CRLM) were analyzed.
    RESULTS: Of 49 patients, 6 (12%) had absent OATP1B3 expression. They had significantly higher ICGR15 value (74.7% vs. 23.5%; p < 0.0001), better modified albumin-bilirubin (ALBI) grade (≤grade 2A, 100% vs. 42%; p = 0.010), more normal 99mTc-GSA hepatic scintigraphy (100% vs. 28%; p = 0.0003), and better pathological liver fibrosis (F0-1, 100% vs. 49%; p = 0.027) compared to those with OATP1B3 expression. Three available frozen blocks of cases without OATP1B3 expression showed homozygous alterations in SLCO1B3. Of 59 patients with CRLM in normal liver background, five (8.5%) had heterozygous insertion in SLCO1B3, however they had no difference in ICGR15 values or other clinical findings compared to the other patients.
    CONCLUSIONS: Constitutional ICG excretory defects may be defined by the complete absence of OATP1B3 expression. The modified ALBI grade and 99mTc-GSA hepatic scintigraphy were useful for detecting constitutional ICG excretory defects.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    肝硬化是一种慢性肝病,是世界上第14位最常见的死亡原因;但它仍然是一种无法治愈的疾病。益生菌作为肝硬化的潜在治疗选择已经获得了显著的普及。
    方法:进行系统评价和荟萃分析以评估益生菌对肝硬化的影响。PubMed,Scopus,从2000年至2024年1月,搜索了Cochrane中央对照试验注册中心(CENTRAL)和ProQuest论文和论文,以评估益生菌对各种肝病结局的影响。
    结果:共有22项随机对照试验研究纳入荟萃分析。益生菌显著降低γ-谷氨酰转移酶(效应大小:-0.307,p=0.024,95%CI[-0.572,-0.040])和天冬氨酸氨基转移酶(p=0.013,95%CI[-17.927,-2.128])。还发现血清氨水平(效应大小=-1.093,p=0.000,95%CI[-1.764,-0.423])和内毒素水平(效应大小=-0.961,p=0.000,95%CI[-1.537,-0.385])显着降低。
    结论:总体益生菌可作为肝硬化患者的潜在辅助治疗,因为它们似乎对改善肝功能有一些好处,耐受性良好,不良反应最小。建议使用更大的样本量进行更全面的研究,以了解更多有关益生菌使用的广泛影响。
    Liver cirrhosis is a chronic condition of the liver and is the 14th most common cause of death around the world; yet it remains an incurable disease. Probiotics have gained significant popularity as a potential treatment option for liver cirrhosis.
    METHODS: A systematic review and meta-analysis was conducted to assess the effects of probiotics on liver cirrhosis. PubMed, Scopus, Cochrane Central Register for Controlled Trials (CENTRAL) and ProQuest Dissertation and Thesis were searched from 2000 to January 2024 for studies that evaluated the effects of probiotics on a variety of outcomes of liver disease.
    RESULTS: A total of 22 randomised controlled trial studies were included in the meta-analysis. Probiotics significantly decreased Gamma-glutamyl transferase (effect size: -0.307, p=0.024, 95% CI [-0.572, -0.040]) and Aspartate aminotransferase (p=0.013, 95% CI [-17.927, -2.128]). Significant reduction in serum ammonia levels (effect size= -1.093, p= 0.000, 95% CI [-1.764, -0.423]) and endotoxin levels (effect size= -0.961, p=0.000, 95% CI [-1.537, -0.385]) were also found.
    CONCLUSIONS: Overall probiotics could be recommended as a potential adjunct therapy for patients with cirrhosis, as they appear to have some benefit in improving liver function, and are well tolerated with minimal adverse effects. More comprehensive research with larger sample sizes is recommended to understand more about the widespread effects of probiotic use.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    关于硒与肝功能参数之间关联的证据有限且存在争议。
    关于膳食硒摄入量的数据,血硒浓度,和肝功能参数来自2017-2020年国家健康和营养检查调查(NHANES)。硒(饮食摄入量和血液浓度)和肝功能参数之间的关联[丙氨酸转氨酶(ALT),天冬氨酸转氨酶(AST),ALT/AST比值,γ-谷氨酰转移酶(GGT),和碱性磷酸酶(ALP)]使用多元线性回归模型进行评估。进行了亚组分析和交互测试,以检查根据年龄,性别,体重指数(BMI),糖尿病,和身体活动。
    该研究包括筛查后的6,869名参与者。多元线性回归模型显示,膳食硒摄入量与ALT(β=0.112,95%CI=0.041,0.183)和ALT/AST比值(β=0.002,95%CI=0.001,0.004)呈正相关。血硒浓度的结果还表明,较高的血硒水平与ALT呈正相关(β=0.436,95%CI=0.308,0.564),AST(β=0.112,95%CI=0.015,0.208),和ALT/AST比值(β=0.012,95%CI=0.009,0.015)。然而,ALP随血硒浓度的增加而降低(β=-0.207,95%CI=-0.414,-0.000)。此外,我们发现硒对肝功能参数的影响显着差异,根据年龄,性别,BMI。
    饮食硒摄入量和血液浓度影响肝功能参数。这些发现表明,需要进一步的研究来探索这些关联,以促进肝脏健康和疾病预防。
    UNASSIGNED: Evidence on the association between selenium and liver function parameters is limited and controversial.
    UNASSIGNED: Data on dietary selenium intake, blood selenium concentration, and liver function parameters were obtained from the National Health and Nutrition Examination Survey (NHANES) 2017-2020. Associations between selenium (dietary intake and blood concentration) and liver function parameters [alanine aminotransferase (ALT), aspartate aminotransferase (AST), the ALT/AST ratio, gamma-glutamyl transferase (GGT), and alkaline phosphatase (ALP)] were assessed using multivariate linear regression models. Subgroup analyses and interaction tests were conducted to examine differences in associations according to age, gender, body mass index (BMI), diabetes, and physical activity.
    UNASSIGNED: The study included 6,869 participants after screening. The multivariate linear regression model revealed that dietary selenium intake was positively associated with ALT (β = 0.112, 95% CI = 0.041, 0.183) and the ALT/AST ratio (β = 0.002, 95% CI = 0.001, 0.004) after adjustment for covariates. Results of blood selenium concentration also showed that higher blood selenium levels were positively associated with ALT (β = 0.436, 95% CI = 0.308, 0.564), AST (β = 0.112, 95% CI = 0.015, 0.208), and the ALT/AST ratio (β = 0.012, 95% CI = 0.009, 0.015). However, ALP decreased with increasing blood selenium concentration (β = -0.207, 95% CI = -0.414, -0.000). In addition, we found significant differences in the effect of selenium on liver function parameters according to age, gender, and BMI.
    UNASSIGNED: Dietary selenium intake and blood concentration affect liver function parameters. These findings suggest that further research is needed to explore these associations to promote liver health and disease prevention.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:肝脏状况是肝细胞癌(HCC)患者的关键预后因素,但是缺乏一种方便而全面的评估肝脏状况的方法。通过二维剪切波弹性成像测量的肝脏硬度(LS)可能有助于评估肝纤维化和肝脏状况。慢性乙型肝炎(CHB)是肝癌进展的重要危险因素,但发现LS在评估肝炎病毒根除后的肝纤维化方面不太可靠。我们假设肝炎病毒感染的状态会影响LS评估肝脏状况的准确性。
    目的:测试使用LS评估HCC和CHB患者肝脏状况的可行性和影响因素。
    方法:根据血清CHB病毒乙型肝炎病毒(HBV)-DNA水平将284例患者回顾性招募并分为两组[HBV-DNA≥100IU/mL作为Pos组(n=200)和<100IU/mL作为Neg组(n=84)]。进行相关性分析和接受者操作特征分析以评估LS与肝脏状况之间的关系。
    结果:发现LS与大多数被认为具有评估肝脏状况的能力的参数之间存在显着相关性(P<0.05)。当丙氨酸转氨酶(ALT)浓度正常(≤40U/L),LS与肝脏状态指标相关(P<0.05),但是,在Neg组(9.30kPa)中,确定Child-Pugh评分为5的LS的最佳临界值高于Pos组(7.40kPa)。当ALT水平升高(>40U/L),LS与肝脏状态指标的相关性不显著(P>0.05)。
    结论:LS与CHB和HCC患者的大多数肝脏状况指标显着相关。然而,这些相关性根据HBV-DNA和转氨酶浓度的差异而变化。
    BACKGROUND: Liver condition is a crucial prognostic factor for patients with hepatocellular carcinoma (HCC), but a convenient and comprehensive method to assess liver condition is lacking. Liver stiffness (LS) measured by two-dimensional shear wave elastography may help in assessing liver fibrosis and liver condition. Chronic hepatitis B (CHB) is an important risk factor for HCC progression, but LS was found to be less reliable in assessing liver fibrosis following hepatitis viral eradication. We hypothesize that the status of hepatitis virus infection would affect the accuracy of LS in assessing the liver condition.
    OBJECTIVE: To test the feasibility and impact factors of using LS to assess liver condition in patients with HCC and CHB.
    METHODS: A total of 284 patients were retrospectively recruited and classified into two groups on the basis of serum CHB virus hepatitis B virus (HBV)-DNA levels [HBV-DNA ≥ 100.00 IU/mL as Pos group (n = 200) and < 100.00 IU/mL as Neg group (n = 84)]. Correlation analyses and receiver operating characteristic analyses were conducted to evaluate the relationship between LS and liver condition.
    RESULTS: A significant correlation was found between LS and most of the parameters considered to have the ability to evaluate liver condition (P < 0.05). When alanine aminotransferase (ALT) concentrations were normal (≤ 40 U/L), LS was correlated with liver condition indices (P < 0.05), but the optimal cutoff of LS to identify a Child-Pugh score of 5 was higher in the Neg group (9.30 kPa) than the Pos group (7.40 kPa). When ALT levels were elevated (> 40 U/L), the correlations between LS and liver condition indices were not significant (P > 0.05).
    CONCLUSIONS: LS was significantly correlated with most liver condition indices in patients with CHB and HCC. However, these correlations varied according to differences in HBV-DNA and transaminase concentrations.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    甘草(甘草属。)一直是中国和日本传统医学的基石。本系统评价和荟萃分析旨在评估甘草制剂的疗效。单独或与其他草药结合使用,对原发性肝病患者肝功能酶的影响。我们系统地搜索了MEDLINE,Embase,Scopus,WebofScience,和Cochrane图书馆截至2024年4月。比较甘草效果的随机对照试验(RCT)。包括与安慰剂或标准护理对照相比的制剂.使用标准Cochrane方法提取数据并评估合格的研究。共15项RCT,涉及1367名参与者,包括在分析中。这些研究在地理位置上差异很大,持续时间,和甘草制剂使用。与对照组相比,甘草显著降低丙氨酸氨基转移酶(ALT)15.63U/L(95%CI:-25.08,-6.18;p=0.001)和天冬氨酸氨基转移酶(AST)7.37U/L(95%CI:-13.13,-1.61;p=0.01)。亚组分析显示,纯化的甘草酸化合物特别有效,显示更多的ALT和AST的减少没有显著的异质性。虽然甘草治疗并没有显著影响γ-谷氨酰转移酶和总胆红素(TBIL)的整体水平,特定的甘草草药制剂确实显示TBIL显着降低。甘草的安全性与已知的副作用一致,主要是轻度的,与其盐皮质激素作用有关。尽管存在异质性和潜在的语言偏见,研究结果表明,甘草可以增强肝功能。进一步的研究应规范甘草制剂,并探索其在多方面的草药配方中的作用,以更好地了解其保肝机制。
    Licorice (Glycyrrhiza spp.) has been a cornerstone of traditional Chinese and Japanese medicine. This systematic review and meta-analysis aimed to evaluate the efficacy of licorice formulations, alone or in combination with other herbs, on liver function enzymes in patients with primary liver disease. We systematically searched MEDLINE, Embase, Scopus, Web of Science, and Cochrane Library up to April 2024. Randomized controlled trials (RCTs) comparing the effects of Glycyrrhiza spp. preparations versus placebo or standard of care controls were included. Standard Cochrane methods were used to extract data and appraise eligible studies. A total of 15 RCTs, involving 1367 participants, were included in the analysis. The studies varied widely in geographical location, duration, and licorice preparations used. Licorice significantly reduced alanine aminotransferase (ALT) by 15.63 U/L (95% CI: -25.08, -6.18; p = 0.001) and aspartate aminotransferase (AST) by 7.37 U/L (95% CI: -13.13, -1.61; p = 0.01) compared to control groups. Subgroup analyses revealed that purified glycyrrhizic acid compounds were particularly effective, showing greater reductions in ALT and AST without significant heterogeneity. Although licorice treatment did not significantly impact gamma-glutamyl transferase and total bilirubin (TBIL) levels overall, specific licorice-herb preparations did show a notable reduction in TBIL. The safety profile of licorice was consistent with known side effects, predominantly mild and related to its mineralocorticoid effects. Despite heterogeneity and potential language bias, the findings suggest that licorice can enhance liver function. Further studies should standardize licorice preparations and explore its role in multifaceted herbal formulations to better understand its hepatoprotective mechanisms.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    华法林由于其临床疗效和价格低廉,已成为需要终身抗凝的患者抗凝的首选。然而,华法林的抗凝作用受到许多药物的影响,食物,等。伴有出血和栓塞的高风险。维生素K环氧化物还原酶复合物1(VKORC1)和细胞色素P4502C9(CYP2C9)基因型变异可影响华法林的治疗剂量。然而,尚不清楚华法林剂量与肝功能之间是否存在相关性,不同基因型患者的肾功能和代谢标志物如尿酸(UA)。我们进行了一项单中心回顾性队列研究,以评估影响华法林剂量的因素,并建立华法林心脏瓣膜置换术患者的剂量转换模型。
    我们研究了343例机械心脏瓣膜置换术患者,比较不同华法林相关基因型(CYP2C9和VKORC1)患者的华法林剂量,并分析了肝功能之间的相关性,肾功能,心脏瓣膜置换术后不同基因型患者的UA和其他代谢标志物以及华法林剂量。
    基因型分析表明,72.01%的患者具有CYP2C9*1/*1和VKORC1突变AA基因型。单因素回归分析显示,华法林维持剂量与性别显著相关,年龄,体表面积(BSA),UA和基因型。与肝肾功能无相关性。多元线性回归分析表明,基因型和UA是影响华法林剂量的独立因素。
    在心脏瓣膜置换基因型CYP2C9*1/*1/VKORC1(GA+GG)患者中,UA含量与华法林剂量之间存在显著相关性,CYP2C9*1/*1/VKORC1AA和CYP2C9*1/*1/VKORC1AA。
    UNASSIGNED: Warfarin has become the first choice for anticoagulation in patients who need lifelong anticoagulation due to its clinical efficacy and low price. However, the anticoagulant effect of warfarin is affected by many drugs, foods, etc. accompanied by a high risk of bleeding and embolism. The Vitamin K epoxide reductase complex 1 (VKORC1) and Cytochrome P450 2C9 (CYP2C9) genotypic variation can influence the therapeutic dose of warfarin. However, it is not clear whether there is a correlation between warfarin dose and liver function, kidney function and metabolic markers such as uric acid (UA) in patients with different genotypes. We performed a single-center retrospective cohort study to evaluate the factors affecting warfarin dose and to establish a dose conversion model for warfarin patients undergoing heart valve replacement.
    UNASSIGNED: We studied 343 patients with a mechanical heart valve replacement, compared the doses of warfarin in patients with different warfarin-related genotypes (CYP2C9 and VKORC1), and analyzed the correlation between liver function, kidney function, UA and other metabolic markers and warfarin dose in patients with different genotypes following heart valve replacement.
    UNASSIGNED: Genotype analysis showed that 72.01% of patients had CYP2C9*1/*1 and VKORC1 mutant AA genotypes. Univariate regression analysis revealed that the warfarin maintenance dose was significantly correlated with gender, age, body surface area (BSA), UA and genotype. There was no correlation with liver or kidney function. Multiple linear regression analysis showed that BSA, genotype and UA were the independent factors influencing warfarin dose.
    UNASSIGNED: There is a significant correlation between UA content and warfarin dose in patients with heart valve replacement genotypes CYP2C9*1/*1/VKORC1(GA+GG), CYP2C9*1/*1/VKORC1AA and CYP2C9*1/*1/VKORC1AA.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    该研究旨在评估水合铝硅酸钙钠(HSCAS)和废弃日期坑(DDP)作为黄曲霉毒素B1(AFB1)的饮食吸附剂如何有效地提高16至30日龄肉鸡的性能和健康。总共240只罗斯308直跑肉鸡被随机分配到四个饮食组中,每个有10个重复:对照饮食,含1000ppbAFB1的对照饮食,含0.5%HSCAS的AFB1污染饮食,和含4%DDP的AFB1污染饮食。将HSCASs或DDP纳入AFB1污染的饮食中,可以显着改善各种参数,涉及体重增加,提高饲料转化率,较高的修整百分比,肾脏和脾脏的相对重量减少,血清总蛋白水平升高,球蛋白,和葡萄糖,血清丙氨酸转氨酶活性降低,肝脏蛋白浓度和谷胱甘肽过氧化物酶活性升高,肝脏丙二醛含量和谷氨酸草酰乙酸转氨酶活性降低。此外,两种补充剂都导致回肠绒毛高度和表面积增加,提高表观氮校正代谢能消化率,肝脏和肾脏中的AFB1残留减少。此外,饮食中含有DDP显著降低相对肝脏重量,血清白蛋白浓度升高,降低血清碱性磷酸酶活性,增强肝脏总抗氧化能力水平,回肠绒毛宽度增大。相反,日粮添加HSCASs可显着提高粗蛋白的表观消化率。总之,在AFB1污染的饮食中加入HSCASs和DDP可以减轻AFB1对肉鸡的毒性作用,DDP在优化肝功能和肠道形态方面表现出额外的优势。
    The research aimed to evaluate how effective hydrated sodium calcium aluminosilicates (HSCASs) and discarded date pits (DDPs) are as dietary adsorbents for aflatoxin B1 (AFB1) in enhancing the performance and health of broiler chickens aged 16 to 30 days. A total of 240 Ross 308 straight-run broilers were randomly allocated into four dietary groups, each with 10 replicates: a control diet, a control diet with 1000 ppb AFB1, an AFB1-contaminated diet with 0.5% HSCAS, and an AFB1-contaminated diet with 4% DDP. Incorporating HSCASs or DDPs into the AFB1-contaminated diet resulted in significant improvements across various parameters, involving increased body weight, improved feed conversion ratio, higher dressing percentage, decreased relative weights of kidney and spleen, elevated serum levels of total protein, globulin, and glucose, reduced serum alanine aminotransferase activity, and heightened hepatic protein concentration and glutathione peroxidase activity, along with diminished hepatic malondialdehyde content and glutamic oxaloacetic transaminase activity. Moreover, both supplements led to increased ileal villus height and surface area, enhanced apparent nitrogen-corrected metabolizable energy digestibility, and decreased AFB1 residues in the liver and kidney. Moreover, the dietary inclusion of DDPs significantly decreased relative liver weight, raised serum albumin concentration, lowered serum alkaline phosphatase activity, enhanced hepatic total antioxidant capacity level, and augmented ileal villus width. Conversely, the dietary addition of HSCASs significantly heightened apparent crude protein digestibility. In conclusion, the inclusion of HSCASs and DDPs in AFB1-contaminated diets can mitigate the toxic effects of AFB1 on broiler chickens, with DDPs exhibiting additional advantages in optimizing liver function and gut morphology.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    声全息(AH),一种有前途的细胞图案化方法,成为构建模仿器官和癌症特征的新型invitro3D模型的强大工具。然而,了解AH后细胞功能的变化仍然有限。此外,仅使用细胞系复制复杂的生理和病理过程被证明具有挑战性。这里,我们采用声学全息晶格将直接从小鼠中分离的原代肝细胞组装到细胞簇基质中,以构建肝形组织样品。第一次,我们评估了AH型原代肝细胞的肝功能。与2D和传统3D培养模型中的细胞相比,图案化模型显示出大量的自组装球体和优越的多种核心肝细胞功能。AH为原代细胞的长期体外培养提供了强大的方案,强调其在疾病发病机理研究中未来应用的潜力,药物测试,和器官替代疗法。
    Acoustic holography (AH), a promising approach for cell patterning, emerges as a powerful tool for constructing novel invitro 3D models that mimic organs and cancers features. However, understanding changes in cell function post-AH remains limited. Furthermore, replicating complex physiological and pathological processes solely with cell lines proves challenging. Here, we employed acoustical holographic lattice to assemble primary hepatocytes directly isolated from mice into a cell cluster matrix to construct a liver-shaped tissue sample. For the first time, we evaluated the liver functions of AH-patterned primary hepatocytes. The patterned model exhibited large numbers of self-assembled spheroids and superior multifarious core hepatocyte functions compared to cells in 2D and traditional 3D culture models. AH offers a robust protocol for long-term in vitro culture of primary cells, underscoring its potential for future applications in disease pathogenesis research, drug testing, and organ replacement therapy.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    目的:肝功能恶化是晚期肝细胞癌(HCC)患者死亡的主要原因。我们评估了免疫检查点抑制剂(ICI)治疗对肝功能和预后的影响。
    方法:包括2003年4月至2024年5月接受ICIs或索拉非尼的HCC患者。在ICI治疗开始时评估肝功能(通过Child-Pugh评分[CPS]评估)(基线,BL)以及此后3个月和6个月。CPS的≥1点变化定义为恶化(-)或改善(+),而相等的CPS点被定义为稳定(=)。
    结果:总体而言,包括182例ICI治疗的患者(66.8±11.8年;肝硬化:n=134,74%)。在BL,中位数CPS为5(IQR:5-6;CPS-A:147,81%)。三个月后,102例(56%)患者肝功能改善/稳定,61例(34%)患者肝功能恶化,而19例(10%)患者死亡/缺失随访(d/noFU)。在6个月时观察到相当的结果(+/=:n=82,45%;-:n=55,30%;d/noFU:n=45,25%)。相比之下,160例索拉非尼患者中的54例(34%)和33例(21%)在3和6个月时实现了改善/稳定,分别。放射学反应与6个月时的CPS改善/稳定有关(反应者与无反应者,73%vs.50%;p=0.007)。根据里程碑分析,6个月时CPS改善/稳定与更好的总生存期相关(6个月:+/=:28.4[95%CI:18.7-38.1]vs-:14.2[95%CI:10.3-18.2]个月;p<0.001)。在35例ICI患者中,CPS-B在BL,16例(46%)患者出现改善/稳定,而19例(54%)患者在3个月时恶化/d/noFU。6个月时观察到可比较的结果(CPS+/=:14,40%,-:8,23%)。重要的是,6/35(17%)和9/35(26%)患者在3和6个月时从CPS-B改善为CPS-A。
    结论:ICI治疗的放射学反应与肝功能的稳定或改善有关,这与生存率的提高有关,即使在基线时Child-PughB级患者中也是如此。
    OBJECTIVE: Deterioration of liver function is a leading cause of death in patients with advanced hepatocellular carcinoma (HCC). We evaluated the impact of immune checkpoint inhibitor (ICI)-treatment on liver function and outcomes.
    METHODS: HCC patients receiving ICIs or sorafenib between 04/2003 and 05/2024 were included. Liver function (assessed by Child-Pugh score [CPS]) was evaluated at the start of ICI-treatment (baseline, BL) and 3 and 6 months thereafter. A ≥1 point change in CPS was defined as deterioration (-) or improvement (+), while equal CPS points were defined as stable (=).
    RESULTS: Overall, 182 ICI-treated patients (66.8 ± 11.8 years; cirrhosis: n = 134, 74%) were included. At BL, median CPS was 5 (IQR: 5-6; CPS-A: 147, 81%). After 3 months, liver function improved/stabilized in 102 (56%) and deteriorated in 61 (34%) patients, while 19 (10%) patients deceased/had missing follow-up (d/noFU). Comparable results were observed at 6 months (+/=: n = 82, 45%; -: n = 55, 30%; d/noFU: n = 45, 25%). In contrast, 54 (34%) and 33 (21%) out of 160 sorafenib patients achieved improvement/stabilization at 3 and 6 months, respectively. Radiological response was linked to CPS improvement/stabilization at 6 months (responders vs. non-responders, 73% vs. 50%; p = 0.007). CPS improvement/stabilization at 6 months was associated with better overall survival following landmark analysis (6 months: +/=: 28.4 [95% CI: 18.7-38.1] versus -: 14.2 [95% CI: 10.3-18.2] months; p < 0.001). Of 35 ICI-patients with CPS-B at BL, improvement/stabilization occurred in 16 (46%) patients, while 19 (54%) patients deteriorated/d/noFU at 3 months. Comparable results were observed at 6 months (CPS +/=: 14, 40%, -: 8, 23%). Importantly, 6/35 (17%) and 9/35 (26%) patients improved from CPS-B to CPS-A at 3 and 6 months.
    CONCLUSIONS: Radiological response to ICI-treatment was associated with stabilization or improvement in liver function, which correlated with improved survival, even in patients with Child-Pugh class B at baseline.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号